Drugs / Mapatumumab
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00712855 | Jun 2008 → Aug 2011 | hepatocellular carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01258608 | Feb 2011 → May 2013 | hepatocellular carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT01088347 | Mar 2010 → Mar 2014 | cervical cancer | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00583830 | Jan 2007 → Nov 2010 | non-small cell lung carcinoma | Human Genome Sciences Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00315757 | May 2006 → Oct 2010 | plasma cell myeloma | Human Genome Sciences Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00094848 | Jun 2004 → Dec 2006 | non-Hodgkin lymphoma | Human Genome Sciences Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00092924 | ? → Jan 2005 | non-small cell lung carcinoma | Human Genome Sciences Inc. | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mapatumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00583830 ↗ |
| Known as | HGS-ETR1 | “TRAIL-R1 mAb (TRM-1; HGS-ETR1)” NCT00094848 ↗1“TRAIL-R1 mAb (TRM-1;HGS-ETR1)” NCT00092924 ↗ |
| Known as | HGS1012 | “A Phase 1B, Multi-center, Open Label, Dose Escalation Study of Mapatumumab ([HGS1012], a Fully-human Monoclonal Antibody to TRAIL-R1) in Combination With Sorafenib as a First...” NCT00712855 ↗2“Mapatumumab (TRM-1 [HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1)” NCT00315757 ↗ “Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1)” NCT01258608 ↗ |
| Known as | TRAIL-R 1MAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108621 ↗ |
| Known as | TRM-1 | “Mapatumumab (TRM-1 [HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1)” NCT00315757 ↗ |
| Known as | TRM-1 HGS-ETR1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108621 ↗ |
| Action | Activate | “mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1)” PMID 24560012 ↗ Dec 20131“TRAIL receptor-1 agonist” CHEMBL2108621 ↗ |
| Modality | Monoclonal antibody | “Fully Human Monoclonal Antibody To TRAIL-R1” NCT00092924 ↗ |
| Route | Intravenous | “10 mg/kg IV (in the vein), on day 1 of each 21-day cycle.” NCT00315757 ↗ |
| Target | TNFRSF10A | “TRAIL receptor-1 agonist” CHEMBL2108621 ↗ |